Hypertriglyceridemia, insulin resistance, and the metabolic syndrome

Research output: Contribution to journalArticle

419 Citations (Scopus)

Abstract

The metabolic syndrome consists of a cluster of metabolic disorders, many of which promote the development of atherosclerosis and increase the risk of cardiovascular disease events. Insulin resistance may lie at the heart of the metabolic syndrome. Elevated serum triglycerides commonly associate with insulin resistance and represent a valuable clinical marker of the metabolic syndrome. Abdominal obesity is a clinical marker for insulin resistance. The metabolic syndrome manifests 4 categories of abnormality: atherogenic dyslipidemia (elevated triglycerides, increased small low- density lipoproteins, and decreased high-density lipoproteins), increased blood pressure, elevated plasma glucose, and a prothrombotic state. Various therapeutic approaches for the patient with the metabolic syndrome should be implemented to decrease the risk of cardiovascular disease events. These interventions include decreasing obesity, increasing physical activity, and managing dyslipidemia; the latter may require the use of pharmacotherapy with cholesterol-lowering and triglyceride-lowering drugs.

Original languageEnglish (US)
JournalAmerican Journal of Cardiology
Volume83
Issue number9 B
StatePublished - May 13 1999

Fingerprint

Hypertriglyceridemia
Insulin Resistance
Triglycerides
Dyslipidemias
Cardiovascular Diseases
Biomarkers
Abdominal Obesity
HDL Lipoproteins
LDL Lipoproteins
Atherosclerosis
Obesity
Cholesterol
Exercise
Blood Pressure
Glucose
Drug Therapy
Serum
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. / Grundy, Scott M.

In: American Journal of Cardiology, Vol. 83, No. 9 B, 13.05.1999.

Research output: Contribution to journalArticle

@article{8992be87ab9e4e2e92fe5e9cdfd10be7,
title = "Hypertriglyceridemia, insulin resistance, and the metabolic syndrome",
abstract = "The metabolic syndrome consists of a cluster of metabolic disorders, many of which promote the development of atherosclerosis and increase the risk of cardiovascular disease events. Insulin resistance may lie at the heart of the metabolic syndrome. Elevated serum triglycerides commonly associate with insulin resistance and represent a valuable clinical marker of the metabolic syndrome. Abdominal obesity is a clinical marker for insulin resistance. The metabolic syndrome manifests 4 categories of abnormality: atherogenic dyslipidemia (elevated triglycerides, increased small low- density lipoproteins, and decreased high-density lipoproteins), increased blood pressure, elevated plasma glucose, and a prothrombotic state. Various therapeutic approaches for the patient with the metabolic syndrome should be implemented to decrease the risk of cardiovascular disease events. These interventions include decreasing obesity, increasing physical activity, and managing dyslipidemia; the latter may require the use of pharmacotherapy with cholesterol-lowering and triglyceride-lowering drugs.",
author = "Grundy, {Scott M}",
year = "1999",
month = "5",
day = "13",
language = "English (US)",
volume = "83",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "9 B",

}

TY - JOUR

T1 - Hypertriglyceridemia, insulin resistance, and the metabolic syndrome

AU - Grundy, Scott M

PY - 1999/5/13

Y1 - 1999/5/13

N2 - The metabolic syndrome consists of a cluster of metabolic disorders, many of which promote the development of atherosclerosis and increase the risk of cardiovascular disease events. Insulin resistance may lie at the heart of the metabolic syndrome. Elevated serum triglycerides commonly associate with insulin resistance and represent a valuable clinical marker of the metabolic syndrome. Abdominal obesity is a clinical marker for insulin resistance. The metabolic syndrome manifests 4 categories of abnormality: atherogenic dyslipidemia (elevated triglycerides, increased small low- density lipoproteins, and decreased high-density lipoproteins), increased blood pressure, elevated plasma glucose, and a prothrombotic state. Various therapeutic approaches for the patient with the metabolic syndrome should be implemented to decrease the risk of cardiovascular disease events. These interventions include decreasing obesity, increasing physical activity, and managing dyslipidemia; the latter may require the use of pharmacotherapy with cholesterol-lowering and triglyceride-lowering drugs.

AB - The metabolic syndrome consists of a cluster of metabolic disorders, many of which promote the development of atherosclerosis and increase the risk of cardiovascular disease events. Insulin resistance may lie at the heart of the metabolic syndrome. Elevated serum triglycerides commonly associate with insulin resistance and represent a valuable clinical marker of the metabolic syndrome. Abdominal obesity is a clinical marker for insulin resistance. The metabolic syndrome manifests 4 categories of abnormality: atherogenic dyslipidemia (elevated triglycerides, increased small low- density lipoproteins, and decreased high-density lipoproteins), increased blood pressure, elevated plasma glucose, and a prothrombotic state. Various therapeutic approaches for the patient with the metabolic syndrome should be implemented to decrease the risk of cardiovascular disease events. These interventions include decreasing obesity, increasing physical activity, and managing dyslipidemia; the latter may require the use of pharmacotherapy with cholesterol-lowering and triglyceride-lowering drugs.

UR - http://www.scopus.com/inward/record.url?scp=0033551397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033551397&partnerID=8YFLogxK

M3 - Article

VL - 83

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 9 B

ER -